All Work

Chris Lange

What to Expect When Pepsi Reports

PepsiCo is one of the first major companies to report earnings this week, with results expected Tuesday morning before the markets open.

Chris Lange · 8 years ago

Constellation Pharma Closes in on IPO

Constellation Pharmaceuticals intends to price more than 5 million shares to result in an initial public offering valued up to more than $98 million.

Chris Lange · 8 years ago

Can Groupon Get Lucky With a Buyout?

Groupon shares have been hit in 2018, but it seems that this online coupon company may have found a way to get something back. Groupon may be looking for a buyout.

Chris Lange · 8 years ago

Friday’s Biggest Winners and Losers in the S&P 500

Friday was a positive day for the broad U.S. markets, closing out an ultimately positive but shortened week. Crude oil bounced back on the day. The S&P 500 sectors were entirely positive.

Chris Lange · 8 years ago

Square Withdraws FDIC Application

Square announced late on Thursday that it would be withdrawing its application with the Federal Deposit Insurance Corporation (FDIC) for a banking charter.

Chris Lange · 8 years ago

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a positive day for the broad U.S. markets, although volume and activity were not so great considering this is the day after a federal holiday. Crude oil backed off on the day.…

Chris Lange · 8 years ago

Micron Bounces Back From Chinese Lawsuit

Micron Technology announced a temporary Chinese ban on a patent infringement lawsuit. Micron’s shares dropped on Tuesday as a result but they have bounced back in Thursday’s session.

Chris Lange · 8 years ago

Why Zynerba Shares Are Getting Crushed

Zynerba Pharmaceuticals shares were crushed early on Thursday after the company reported topline results from an early stage clinical study.

Chris Lange · 8 years ago

Clovis Breaks Into Europe With EMA Validation

Clovis Oncology shares saw a bump early on Thursday after the company announced that the European Medicines Agency has validated its application for a Type 2 variation to the marketing authorization for Rubraca.

Chris Lange · 8 years ago